IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

<div>ROC curve analysis of the anti-GlcNAc<i>β</i> IgG level in HCV-1b carriers with stages F0 and F1–4.</div>

Disease Markers

fig3

Figure 3

Figure 3: IgG Antibodies to GlcNAc<i>β</i> and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 

Figure 3 | IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment 